NEW YORK, Jan. 12, 2023 /PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Dendritic Cell Cancer Vaccine Market Share, Size, Trends, Industry Analysis Report, By Product; By End-Use; By Region; Segment Forecast, 2023-2032" published by Polaris Market Research in its research repository.
As per recent research study, the global dendritic cell cancer vaccine market size was valued at USD 596.65 million in 2022 and is expected to reach USD 1,841.54 Million by 2032, growing at a CAGR of 11.9% during the forecast period.
What is Dendritic Cell Cancer Vaccines? How Big is Dendritic Cell Cancer Vaccine Market Size?
- Overview
Dendritic cell cancer vaccines induce specific immune responses that can individually eliminate target cells. Many studies are being conducted to explore DC vaccination to cure hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes, as well as other non-leukemia malignancies. The rapidly rising demand for the dendritic cell cancer vaccine market can be attributed to the fact that due to their capacity for antigen presentation, DCs are principal organizers in the induction of antitumor immunity.
The growth of the market is credited to elements such as escalating clinical trial activity connected to cancer vaccines, increasing demand for mRNA-based vaccines together with expanding cancer remedies. The increasing demand for constructive and customized treatments is influencing the market's growth.
Request Sample Copy of Dendritic Cell Cancer Vaccine Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-sample
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)
Our Sample Report May Includes:
- 2030 Updated Report Introduction, Overview, and In-depth industry analysis
- 115+ Pages Research Report (Inclusion of Updated Research)
- Provide Chapter-wise guidance on Request
- 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
- Includes Updated List of table & figures
- Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
Some of the Top Market Players Are:
- 3M Company
- Activartis
- Argos Therapeutics
- Batavia Bioservices
- DanDrit Biotech Corporation
- DCPrime
- Elios Therapeutics
- GlaxoSmithKline
- ImmunoCellular Therapeutics
- Sanpower Corporation
To know an additional revised list of top market players, request a sample report, 2023 - 2032: https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-sample
Key Highlights of the Report
- Qualitative and quantitative analysis of the market based on segmentation, including both economic as well as non-economic factors
- Supplying market value data for each segment and sub-segment
- Points to the region and segment that is anticipated to witness the fastest growth
- Analysis by geography underscoring the intake of the product or service in the region as well as designating the factors that are impacting the market within each region
- Substantial company profiles consisting of company overview, company insights, product benchmarking, and SWOT analyses for major market players
Growth Driving Factors
- An increasing number of cancer patients globally pushes the market
The market is gaining traction due to the escalating number of cancer patients globally. The alterations in lifestyle, such as chewing tobacco, smoking, and drinking alcohol, have notably enhanced the figure of cancer patients globally, thereby offering an ascend to the market. The dendritic cell cancer vaccine market size is expanding as it is attracting the attention of several prospective investors and stakeholders due to a remunerative advancement in the pipeline.
The dendritic cell vaccine immunotherapy has transformed the market with its exciting new range of techniques. The dendritic cell cancer vaccine market sales are soaring as, in contrast with chemotherapy and radiation therapy, these new techniques are bereft of side effects. The global healthcare industry for cancer was in pressing need of encouraging treatment where patients could have increased five-year survival rate, slightest side effects, improvised targeting capacity of the controlled cells, and many more.
Directly Purchase a copy of report with TOC @ https://www.polarismarketresearch.com/checkouts/19491
Recent developments
· In June 2018, Northwest Bio-therapeutics secured FDA clearance for its dendritic cell-based vaccine, DCVax-L, utilized to cure glioblastoma cancers. Its clinical globe exemplified that many patients lived for more than a year after getting the immunization.
Segmental Analysis
- The sipuleucel-T segment emerged with the highest revenue share
Based on product, the Sipuleucel-T segment emerged with the highest revenue share. Sipuleucel-T's potential to profitably boost an individual's immunity against tumor cells escalates its market demand. The vaccine was licensed by the US Food and Drug Administration in 2010 for the cure of castrate-resistant prostate cancer. Dendritic cell cancer vaccine market demand is rising as Sipuleucel-T increases immunity with sparse adverse effects and enhances the survivor's longevity.
- Adults segment dominated the market
Based on end use, the adults segment dominated the market due to escalated cases of malignancies globally. Dendritic cell cancer vaccine market trends include several researchers globally attempting to carry out substantial studies to generate feasible vaccine candidates so that possible treatment techniques can be accomplished.
Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/inquire-before-buying
(Inquire a report quote OR available discount offers to the sales team before purchase.)
Dendritic Cell Cancer Vaccine Market: Report Scope
Report Attribute |
Details |
Revenue forecast in 2032 |
USD 1,841.54 Million |
Market size value in 2023 |
USD 667.29 Million |
Expected CAGR Growth |
11.9 % from 2023 - 2032 |
Base Year |
2021 |
Forecast Year |
2023 - 2032 |
Top Market Players |
3M Company, Activartis, Argos Therapeutics, Batavia Bioservices, , DanDrit Biotech Corporation, DCPrime, Elios Therapeutics, GlaxoSmithKline, ImmunoCellular Therapeutics, Sanpower Corporation |
Segments Covered |
By Product, By End-Use, By Region |
Customization Options |
Customized purchase options are available to meet any research needs. Explore customized purchase options |
Geographic Overview
- Substantially funded research studies to drive the North American market
North America held the largest dendritic cell cancer vaccine market share due to an unusual increase in cancer cases and considerable research studies funded by university research institutes and pharmaceutical behemoths. For instance, researchers at Memorial Sloan Kettering Cancer Centre in the United States have been studying mRNA vaccine technology. They will debate the phase 1 trial outcomes at the American Society of Clinical Oncology's annual conference. It is a known fact that mRNA vaccines boost dendritic cells to generate neo-antigen proteins against cancerous cells.
Europe is anticipated to possess sizeable market expansion in the future years. This can be attributed to the growing demand for cancer vaccines, growing cancer cases, and heightened reinforcement for research projects from the cancer societies, all of which commit to the market's growth.
Browse the Detail Report "Dendritic Cell Cancer Vaccine Market Share, Size, Trends, Industry Analysis Report, By Product; By End-Use; By Region; Segment Forecast, 2023-2032" with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market
For Additional Information OR Media Enquiry, Please Mail At: [email protected]
Polaris Market Research has segmented the dendritic cell cancer vaccine market report based on product, end-use, and region:
By Product Outlook
- CreaVax
- Sipuleucel-T
- Others
By End Use Outlook
- Paediatrics
- Adults
By Region Outlook
- North America (U.S., Canada)
- Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
- Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
- Latin America (Brazil, Mexico, Argentina)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
Contact:
Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: [email protected]
Web: https://www.polarismarketresearch.com
Follow US: LinkedIn | twitter
Logo: https://mma.prnewswire.com/media/1316207/Polaris_Market_Research_Logo.jpg
SOURCE Polaris Market Research
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article